Focus on Lymphoid Malignancies (Volume 5, Issue 4.1)

Focus on Lymphoid Malignancies

Volume 5, Issue 4.1

This supplement features a look at the future of Hodgkin lymphoma treatment, the latest approvals for lymphoid malignancies, and more.

Table of Contents

Newly Approved Drugs

The Year in FDA Approvals

Thursday, March 7th, 2019
In the past year, the U.S. Food and Drug Administration (FDA) approved a record-breaking number of drugs, several of which were indicated for the...

In the Literature

Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma

Thursday, March 7th, 2019
New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...

BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma

Thursday, March 7th, 2019
In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...

Study of Single-Agent Nivolumab in Patients With Relapsed/Refractory DLBCL Fails to Meet Endpoint

Thursday, March 7th, 2019
Treatment with single-agent nivolumab was associated with “disappointingly low” response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to...

Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial

Thursday, March 7th, 2019
According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...

Meeting News

Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial

Thursday, March 7th, 2019
For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT), a standard salvage therapy approach involves high-dose chemotherapy and...

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

Thursday, March 7th, 2019
For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of the BCL2 protein, combining the BCL2 inhibitor venetoclax with...

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

Thursday, March 7th, 2019
For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response rates and prolonged time to next treatment, compared with...

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Thursday, March 7th, 2019
Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome inhibitor (PI) ixazomib in patients with newly diagnosed multiple...


Is the Era of Traditional Chemotherapy for Hodgkin Lymphoma Over?

Thursday, March 7th, 2019
Treatment of Hodgkin lymphoma (HL) has been one of the greatest success stories in oncology, with the invention of radiation therapy and combination chemotherapy...